Quoin Pharmaceuticals (QNRX, Financial) has unveiled the second episode in its "Living with Netherton" video series, an integral component of its NETHERTON NOW awareness initiative. This latest episode highlights the journey of Norma Coles, a 79-year-old woman who was diagnosed with Netherton Syndrome years after first seeing Dr. Edward Netherton, the condition's namesake. Her story underscores the critical need for innovative treatments.
Currently, there are no FDA-approved treatments for Netherton Syndrome, a fact that amplifies the importance of ongoing research. Quoin Pharmaceuticals is at the forefront of this effort with its QRX003 clinical trials. These trials have revealed promising initial outcomes, demonstrating significant improvements in skin healing, reduced inflammation and discomfort, and overall enhancements in patient quality of life.
As Quoin Pharmaceuticals continues its work, its commitment to delivering a transformative treatment remains steadfast, fueled by personal stories like that of Norma Coles. The company aims to achieve a breakthrough that could lead to the first approved treatment for this challenging condition, offering hope to patients who have endured lengthy and arduous medical journeys.
